MBNL1 and myotonic dystrophy type 1: The approach led to the identification of furamidine (Table S2), which is capable of binding to CUG RNA, disrupting MBNL1 binding, reducing ribonuclear foci, and rescuing mis-splicing in DM1 cell models and the HSALR DM1 mouse model.